美国食品药品监督管理局的2025年警告删除增加了需求,导致美国缺乏透皮雌激素贴片. FDA's 2025 warning removal boosted demand, causing U.S. shortages of transdermal estrogen patches.

由于FDA将在2025年取消雌激素产品的黑警告, 导致更年期激素治疗需求激增, 导致美国广泛缺乏透皮雌激素贴片, 使患者和医生难以获得处方. A surge in demand for menopause hormone therapy, driven by the FDA's 2025 removal of a black-box warning on estrogen products, has led to widespread shortages of transdermal estrogen patches in the U.S., leaving patients and doctors struggling to access prescriptions. 尽管治疗越来越被接受为比口服形式更安全(由于血液凝块减少和心脏病发作的风险降低),但供应却未能跟上步伐,造成延误,迫使一些人转向网上药店。 Despite the therapy's growing acceptance as safer than oral forms—due to reduced blood clot and heart attack risks—supply has failed to keep pace, causing delays and forcing some to turn to online pharmacies. 卫生专家指出,在不断变化的医疗指导中,情况暴露了供应链准备状态的差距。 Health experts note the situation exposes gaps in supply chain readiness amid shifting medical guidance.